ArticleMedicine2026
Autism spectrum disorder burden in China and worldwide, 1990-2021: A comparative ecological time-series study using global burden of disease 2021 data.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Autism spectrum disorder (ASD) imposes a substantial public health burden. This study quantified and compared the ASD burden in China and globally from 1990 to 2021 to inform policy and planning. We analyzed Global Burden of Disease 2021 estimates of age-standardized prevalence rates (ASPR) and age-standardized disability-adjusted life-year rates (ASDR) in China and worldwide, with analyses by sex and age. Joinpoint regression characterized historical trends. Autoregressive integrated moving average (ARIMA) models generated exploratory projections for 2022 to 2031; no temporal holdout validation or comparison with alternative forecasting approaches was performed. In 2021, ASPR per 100,000 population was 655.75 (95% uncertainty interval [UI] 545.06-780.37) in China and 788.34 (95% UI 663.76-927.21) globally; ASDR was 124.19 (95% UI 83.70-175.10) and 147.56 (95% UI 100.21-208.16), respectively. From 1990 to 2021, the average annual percent changes in ASPR and ASDR were 0.22% (95% confidence interval [CI] 0.21-0.24) and 0.23% (95% CI 0.21-0.25) in China, compared with 0.06% (95% CI 0.06-0.07) and 0.07% (95% CI 0.06-0.08) globally. The estimated burden was higher in males. The exploratory ARIMA point projections suggested a modest decline in ASPR in both settings and in global ASDR but an increase in China's ASDR. These directions have not been validated out of sample. Historical estimates indicate an increasing ASD burden in China and worldwide. The ARIMA results represent model-based scenarios, not validated future trajectories. The existing burden supports sustained attention to early identification, long-term care, and family support; resource planning should not rely on these projections alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.